Funding news
Wynveris logo

Wynveris Raises $44K

Recently funded · $44.5K UnknownHospitals and Health CareView source

Get the full Wynveris company profile

Access contacts, investors, buying signals & more

Open in Dashboard

The Wnt pathway, a notorious driver of cancer growth and drug resistance, has long stumped pharmaceutical researchers, with every broad Wnt inhibition program failing due to severe toxicity. Now, Wynveris, a biotech startup developing first-in-class receptor-selective Wnt inhibitors, has secured $44K in new funding to advance its novel approach.

Wynveris aims to overcome decades of failed attempts by targeting only the specific Wnt receptors a tumor depends on. This precision allows healthy tissue to rely on other receptors, promising to hit cancer hard without the prohibitive side effects that plagued prior treatments and made them too toxic to dose effectively.

Other recently funded companies

View all

Biggest recent Biotechnology rounds

Largest funding rounds in Biotechnology on Signalbase right now.

#CompanyAmount
1
Shockwave Medical logo

Shockwave Medical

United States

$13.1B
2
NeuroEM Therapeutics logo

NeuroEM Therapeutics

United States

$7.2B
3
Illumina logo

Illumina

United States

$7.1B
4
GRAIL logo

GRAIL

United States

$7.1B
5
RemeGen Biosciences logo

RemeGen Biosciences

United States

$5.6B

Other recent Unknown rounds

Companies that recently closed a Unknown round.

#CompanyAmount
1
Safe-Sight.Ai logo

Safe-Sight.Ai

Australia

$44.5K
2
Eddy Grid logo

Eddy Grid

The Netherlands

$8.5M
3
CloudWalk, Inc. logo

CloudWalk, Inc.

Brazil

$1.1B
4
CargoX logo

CargoX

$250.0M
5
Global Africa Telesud logo

Global Africa Telesud

France

$232.9K